ES2922749T3 - Composiciones de sabor agradable que incluyen fenilbutirato de sodio y sus usos - Google Patents

Composiciones de sabor agradable que incluyen fenilbutirato de sodio y sus usos Download PDF

Info

Publication number
ES2922749T3
ES2922749T3 ES16894786T ES16894786T ES2922749T3 ES 2922749 T3 ES2922749 T3 ES 2922749T3 ES 16894786 T ES16894786 T ES 16894786T ES 16894786 T ES16894786 T ES 16894786T ES 2922749 T3 ES2922749 T3 ES 2922749T3
Authority
ES
Spain
Prior art keywords
taste
pharmaceutical composition
total weight
sodium phenylbutyrate
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16894786T
Other languages
English (en)
Spanish (es)
Inventor
Leah E Appel
Joshua R Shockey
D Christopher Schelling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acer Therapeutics Inc
Original Assignee
Acer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc filed Critical Acer Therapeutics Inc
Application granted granted Critical
Publication of ES2922749T3 publication Critical patent/ES2922749T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
ES16894786T 2016-03-15 2016-10-17 Composiciones de sabor agradable que incluyen fenilbutirato de sodio y sus usos Active ES2922749T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15
PCT/US2016/057415 WO2017160345A1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof

Publications (1)

Publication Number Publication Date
ES2922749T3 true ES2922749T3 (es) 2022-09-20

Family

ID=59847918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16894786T Active ES2922749T3 (es) 2016-03-15 2016-10-17 Composiciones de sabor agradable que incluyen fenilbutirato de sodio y sus usos

Country Status (22)

Country Link
US (6) US20170266115A1 (enExample)
EP (2) EP3429559B1 (enExample)
JP (4) JP7136763B2 (enExample)
KR (3) KR102690703B1 (enExample)
AU (1) AU2016398029B2 (enExample)
BR (1) BR112018068665B1 (enExample)
CY (1) CY1125450T1 (enExample)
DK (1) DK3429559T3 (enExample)
ES (1) ES2922749T3 (enExample)
HR (1) HRP20220856T1 (enExample)
HU (1) HUE059630T2 (enExample)
IL (3) IL322955A (enExample)
LT (1) LT3429559T (enExample)
MX (2) MX391305B (enExample)
PL (1) PL3429559T3 (enExample)
PT (1) PT3429559T (enExample)
RS (1) RS63383B1 (enExample)
SA (1) SA518400020B1 (enExample)
SG (1) SG11201807979SA (enExample)
SI (1) SI3429559T1 (enExample)
SM (1) SMT202200386T1 (enExample)
WO (1) WO2017160345A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391305B (es) 2016-03-15 2025-03-21 Acer Therapeutics Inc Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
WO2022011061A1 (en) * 2020-07-07 2022-01-13 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor
EP4247354A4 (en) * 2020-11-18 2025-02-19 Fb-Hrs, Llc COMPOSITIONS CONTAINING DOFETILIDE AND MEXILETINE AND THEIR USES
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale
CN216570857U (zh) * 2021-08-11 2022-05-24 Acer治疗公司 改善药物物质适口性的剂型和多个剂型
IL315049A (en) * 2024-08-15 2026-03-01 Prilenia Neurotherapeutics Ltd Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
JP2005060310A (ja) 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ATE378042T1 (de) * 2004-04-12 2007-11-15 Pfizer Prod Inc Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
US8821928B2 (en) * 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
US20100136110A1 (en) * 2008-09-30 2010-06-03 Astellas Pharma Inc. Granular pharmaceutical composition for oral administration
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
WO2012077038A1 (en) 2010-12-06 2012-06-14 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
US8897280B2 (en) * 2011-03-29 2014-11-25 Qualcomm Incorporated System and method for clear channel assessment that supports simultaneous transmission by multiple wireless protocols
EP2709593A4 (en) * 2011-05-16 2014-10-29 Sun Pharma Advanced Res Co Ltd PHARMACEUTICAL COMPOSITION OF MULTIPLE PARTICLES
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
CN103687496A (zh) 2011-06-07 2014-03-26 Spai集团有限公司 用于改善敏感性食品添加剂及其食品产品的稳定性并且延长其货架期的组合物和方法
JP2014517057A (ja) * 2011-06-22 2014-07-17 ジーエムピー‐オーファン 運動ニューロン疾患または代謝性疾患の治療のための直腸形態のフェニル酪酸塩
KR20140057604A (ko) * 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US8993041B2 (en) 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
CN105560203A (zh) 2013-01-28 2016-05-11 万平 定位速释生物粘附剂及其制备方法和应用
JP6147711B2 (ja) 2014-05-26 2017-06-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
MX391305B (es) 2016-03-15 2025-03-21 Acer Therapeutics Inc Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.

Also Published As

Publication number Publication date
DK3429559T3 (da) 2022-07-11
PL3429559T3 (pl) 2022-11-07
KR20240119184A (ko) 2024-08-06
HRP20220856T1 (hr) 2022-10-14
BR112018068665A2 (pt) 2019-02-05
AU2016398029B2 (en) 2023-03-02
JP7136763B2 (ja) 2022-09-13
MX391305B (es) 2025-03-21
SA518400020B1 (ar) 2022-12-21
PT3429559T (pt) 2022-07-20
MX2022003969A (es) 2022-04-25
US20230133629A1 (en) 2023-05-04
CY1125450T1 (el) 2025-05-09
JP2022106927A (ja) 2022-07-20
IL261777A (en) 2018-10-31
IL296490B2 (en) 2026-01-01
CA3017573A1 (en) 2017-09-21
JP2026027401A (ja) 2026-02-18
EP3429559A4 (en) 2019-11-06
IL322955A (en) 2025-10-01
IL261777B2 (en) 2023-02-01
US20210220304A1 (en) 2021-07-22
AU2016398029A1 (en) 2018-10-11
BR112018068665B1 (pt) 2023-12-26
US20170266115A1 (en) 2017-09-21
KR20250150154A (ko) 2025-10-17
US11202767B2 (en) 2021-12-21
IL261777B (en) 2022-10-01
LT3429559T (lt) 2022-08-10
HUE059630T2 (hu) 2022-11-28
US11433041B2 (en) 2022-09-06
KR20190008840A (ko) 2019-01-25
EP3429559A1 (en) 2019-01-23
US20210186908A1 (en) 2021-06-24
MX2018011229A (es) 2019-05-30
US20260076927A1 (en) 2026-03-19
JP2024081748A (ja) 2024-06-18
RS63383B1 (sr) 2022-08-31
EP3429559B1 (en) 2022-04-13
SMT202200386T1 (it) 2022-11-18
US11154521B2 (en) 2021-10-26
KR102865751B1 (ko) 2025-09-29
IL296490A (en) 2022-11-01
EP4104822A1 (en) 2022-12-21
WO2017160345A1 (en) 2017-09-21
SG11201807979SA (en) 2018-10-30
IL296490B1 (en) 2025-09-01
KR102690703B1 (ko) 2024-08-02
SI3429559T1 (sl) 2022-11-30
JP2019509345A (ja) 2019-04-04
WO2017160345A8 (en) 2018-02-22
US20200261385A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
US20260076927A1 (en) Palatable compositions including sodium phenylbutyrate and uses thereof
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
RU2690685C2 (ru) Фармацевтические композиции, содержащие алпелисиб
CA2765172A1 (en) Novel pharmaceutical compositions containing pregabalin
EP2934540B1 (en) Methods for treating gi tract disorders
BR112016011142B1 (pt) Composições orais sólidas de liberação lenta
RS54447B1 (sr) Modifikovano oslobađajuće kompozicije epalrestata ili njegovih derivata i postupci njihove upotrebe
WO2016154313A1 (en) High drug loading liquid oral pharmaceutical compositions
CA3017573C (en) Palatable compositions including sodium phenylbutyrate and uses thereof
JP2003512311A (ja) Ｃｎｓ介在性障害を治療するための持続放出製剤
ES2317450T3 (es) Formulacion de liberacion controlada de acido valproico y sus derivados.